N/A
Completed N=41
Transcend Auto vs Commercially Available Device Clinical Evaluation for Treatment of Obstructive Sleep Apnea (OSA)
Source: ClinicalTrials.gov NCT01799265 ↗Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcomePrimary: Mean Apnea Hypopnea Index (AHI) During Treatment — 2.1; 2.0 AHI — p=.05
Summary
The purpose of this study is to determine whether the Transcend Auto is as effective in treating obstructive sleep apnea as another device that is already on the market.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Apnea Hypopnea Index (AHI) During Treatment |
2.1; 2.0 | .05 |
| SECONDARY Unanticipated Adverse Device Effects |
0; 0 | — |
| SECONDARY Mean Differences Between Polysomnography (PSG) and Device Measures of Apnea Index (AI) and Hypopnea Index (HI) |
-0.7; 0.2 | — |
Eligibility Criteria
Inclusion Criteria
- Adult 18 years of age or older
- Diagnosis of obstructive sleep apnea
- Presently using CPAP or APAP therapy
Exclusion Criteria
- Central or mixed apnea
Data sourced from ClinicalTrials.gov (NCT01799265). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.